What is Biocytogen?
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology firm dedicated to advancing the development of innovative antibody-based therapeutics. Leveraging its proprietary RenMice platform for fully human antibody discovery, coupled with in vivo drug efficacy screening and robust clinical development expertise, Biocytogen aims to accelerate the drug development lifecycle. The company's RenMice HiTS Platform is designed to create first-in-class and/or best-in-class antibody drugs targeting over 1000 distinct targets, fostering collaborations with numerous partners worldwide. Biocytogen's pipeline features 12 core products, with two currently in Phase II multi-regional clinical trials (MRCTs) and two in Phase I trials. The company operates globally with headquarters in Beijing and branches in Haimen, Shanghai, Boston, and Heidelberg.
How much funding has Biocytogen raised?
Biocytogen has raised a total of $60M across 1 funding round:
Stock Offering
$60M
Stock Issuance/Offering (2022): $60M, investors not publicly disclosed
What's next for Biocytogen?
The substantial enterprise-level funding, highlighted by the recent strategic investment, positions Biocytogen for accelerated expansion and further pipeline development. This capital infusion is expected to fuel the advancement of its core products through critical clinical trial phases and potentially broaden its collaborative efforts. The company's focus on developing novel antibody drugs with first-in-class or best-in-class potential suggests a strategic direction aimed at addressing unmet medical needs and capturing significant market share in the competitive biopharmaceutical landscape.
See full Biocytogen company page
